Transparency notification pursuant to Article 14 of the Law of May 2, 2007
June 14 2018 - 4:01PM
REGULATED INFORMATIONPRESS
RELEASE
Transparency notification pursuant to Article
14 of the Law of May 2, 2007
Leuven (Belgium) - June 14, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix")
announced today that it received a transparency notification
pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding
the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions.
Summary of the notification
On June 11, 2018, TiGenix received a
transparency notification from Melqart Asset Management LP (c/o
Melqart Asset Management (UK) Ltd), following the disposal of
financial instruments that are treated as voting securities on June
8, 2018, after which Melqart Asset Management LP (through its
controlled entity Melqart Asset Management (UK) Ltd) downward
crossed the lowest threshold (3%) of total voting rights of
TiGenix.
Content of the notification of Melqart Asset
Management LP
Date of the notification: June 11, 2018.
Reason of the notification: acquisition or
disposal of financial instruments that are treated as voting
securities/downward crossing of the lowest threshold.
Person subject to the notification requirement:
Melqart Asset Management LP c/o Melqart Asset Management (UK) Ltd
(with address at PO Box 309, Ugland House, Grand Cayman,
KY1-1104), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: June 8,
2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: following the
disposal of financial instruments that are treated as voting
securities, the number of voting rights was as follows:
- Melqart Asset Management LP c/o Melqart Asset Management (UK)
Ltd held 0 voting securities,
and the number of equivalent financial instruments was as
follows:
- Melqart Asset Management (UK) Ltd held 0 voting rights that may
be acquired if the instrument (cash settled derivative) is
exercised (0% of the total number of voting rights).
Chain of controlled undertakings through which
the holding is effectively held: Melqart Asset Management LP
controls Melqart Asset Management (UK) Ltd.
Additional information: Melqart Asset Management
(UK) Ltd is the investment manager of Melqart Opportunities Master
Fund Ltd. Melqart Asset Management (UK) Ltd is a management company
that can exercise the voting rights at its own discretion without
specific instructions.
This press release and the above-mentioned transparency
notification can be consulted on our website:
- press release:
http://tigenix.com/news-media/press-releases
- notifications:
http://tigenix.com/investors/share-information/shareholder-overview
For more information:
TiGenixClaudia JiménezSenior Director Investor
Relations and CommunicationsTel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024